Foghorn Therapeutics (FHTX) Change in Account Payables (2019 - 2026)
Foghorn Therapeutics' (FHTX) quarterly Change in Account Payables came in at -$990000.0 in Q1 2026, down 448.59% year-on-year from $284000.0 in Q1 2025, and down 193.93% quarter-over-quarter from $1.1 million in Q4 2025.
Foghorn Therapeutics (FHTX) Change in Account Payables (2019 - 2026) Analysis & Trends
Foghorn Therapeutics' Change in Account Payables history runs 8 years deep, the most recent figure standing at -$990000.0 for Q1 2026.
- On a quarterly basis, Change in Account Payables fell 448.59% year-over-year to -$990000.0 in Q1 2026; TTM through Mar 2026 was -$793000.0, a 49.23% increase from a year earlier, with the FY2025 full-year figure at $481000.0, up 119.43% from the prior year.
- Change in Account Payables fell to -$990000.0 in Q1 2026 per FHTX's latest filing, from $1.1 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $1.7 million in Q1 2023 and bottomed at -$1.4 million in Q2 2022.
- The 5-year median for Change in Account Payables is -$171000.0 (2023), against an average of -$30823.5.
- Across the five-year window, Change in Account Payables soared 847.62% in 2022 and sank 448.59% in 2026, its largest moves.
- Year by year, Change in Account Payables stood at $157000.0 in 2022, then tumbled by 250.32% to -$236000.0 in 2023, then surged by 241.53% to $334000.0 in 2024, then soared by 215.57% to $1.1 million in 2025, then sank by 193.93% to -$990000.0 in 2026.
- Per Business Quant, the three latest FHTX Change in Account Payables figures stand at -$990000.0 (Q1 2026), $1.1 million (Q4 2025), and -$110000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -42.19 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.52 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 16.86 Mn |
| 10 | Foghorn Therapeutics | 352.57 Mn | 263.66 Mn | - | -990,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -990,000.00 |
| Mar 31, 2026 | -990,000.00 |
| Dec 31, 2025 | 1.05 Mn |
| Dec 31, 2025 | 1.05 Mn |
| Sep 30, 2025 | -110,000.00 |
| Sep 30, 2025 | -110,000.00 |
| Jun 30, 2025 | -747,000.00 |
| Jun 30, 2025 | -747,000.00 |
| Mar 31, 2025 | 284,000.00 |
| Mar 31, 2025 | 284,000.00 |
| Dec 31, 2024 | 334,000.00 |
| Dec 31, 2024 | 334,000.00 |
| Sep 30, 2024 | -1.35 Mn |
| Sep 30, 2024 | -1.35 Mn |
| Jun 30, 2024 | -829,000.00 |
| Jun 30, 2024 | -829,000.00 |
| Mar 31, 2024 | -629,000.00 |
| Mar 31, 2024 | -629,000.00 |
| Dec 31, 2023 | -236,000.00 |
| Dec 31, 2023 | -236,000.00 |